Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial o...
DARMSTADT, Germany and NEW YORK, Dec. 22, 2018 /PRNewswire-AsiaNet/-- Not intended for US, Canada and UK-based mediaMerck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypo...
Read more https://view-release/?pr-id=76888